Qki regulates myelinogenesis through Srebp2-dependent cholesterol biosynthesis

  1. Xin Zhou
  2. Seula Shin
  3. Chenxi He
  4. Qiang Zhang
  5. Matthew N Rasband
  6. Jiangong Ren
  7. Congxin Dai
  8. Rocío I Zorrilla-Veloz
  9. Takashi Shingu
  10. Liang Yuan
  11. Yunfei Wang
  12. Yiwen Chen
  13. Fei Lan
  14. Jian Hu  Is a corresponding author
  1. MD Anderson Cancer Center, United States
  2. Fudan University, China
  3. Baylor College of Medicine, United States
  4. Chinese Academy of Medical Sciences and Peking Union Medical College, China
  5. Tufts University, United States

Abstract

Myelination depends on timely, precise control of oligodendrocyte differentiation and myelinogenesis. Cholesterol is the most abundant component of myelin and essential for myelin membrane assembly in the central nervous system. However, the underlying mechanisms of precise control of cholesterol biosynthesis in oligodendrocytes remain elusive. In the present study, we found that Qki depletion in neural stem cells or oligodendrocyte precursor cells in neonatal mice resulted in impaired cholesterol biosynthesis and defective myelinogenesis without compromising their differentiation into Aspa+Gstpi+ myelinating oligodendrocytes. Mechanistically, Qki-5 functions as a co-activator of Srebp2 to control transcription of the genes involved in cholesterol biosynthesis in oligodendrocytes. Consequently, Qki depletion led to substantially reduced concentration of the cholesterol in mouse brain, impairing proper myelin assembly. Our study demonstrated that Qki-Srebp2–controlled cholesterol biosynthesis is indispensable for myelinogenesis and highlights a novel function of Qki as a transcriptional co-activator beyond its canonical function as an RNA-binding protein.

Data availability

Sequencing data have been deposited in GEO under accession codes GSE145116, GSE145117 and GSE144756

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Xin Zhou

    Department of Cancer Biology, MD Anderson Cancer Center, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Seula Shin

    Department of Cancer Biology, MD Anderson Cancer Center, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Chenxi He

    Liver Cancer Institute, Fudan University, Shanghai, China
    Competing interests
    The authors declare that no competing interests exist.
  4. Qiang Zhang

    Department of Cancer Biology, MD Anderson Cancer Center, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Matthew N Rasband

    Department of Neuroscience, Baylor College of Medicine, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8184-2477
  6. Jiangong Ren

    Department of Cancer Biology, MD Anderson Cancer Center, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Congxin Dai

    Department of Neurosurgery, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  8. Rocío I Zorrilla-Veloz

    Department of Cancer Biology, MD Anderson Cancer Center, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Takashi Shingu

    Department of Cancer Biology, MD Anderson Cancer Center, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Liang Yuan

    Graduate School of Biomedical Sciences, Tufts University, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Yunfei Wang

    Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Yiwen Chen

    Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Fei Lan

    Liver Cancer Institute, Fudan University, Shanghai, China
    Competing interests
    The authors declare that no competing interests exist.
  14. Jian Hu

    Department of Cancer Biology, MD Anderson Cancer Center, Houston, United States
    For correspondence
    JHu3@mdanderson.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9760-2013

Funding

NCI (R37CA214800)

  • Jian Hu

MD Anderson Cancer Center (startup)

  • Jian Hu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All mouse experiments were conducted in accordance with protocols approved by the MD Anderson Institutional Animal Care and Use Committee. (IACUC Study #00001392-RN01)

Reviewing Editor

  1. Jian Xu, University of Texas Southwestern Medical Center, United States

Publication history

  1. Received: June 26, 2020
  2. Accepted: May 1, 2021
  3. Accepted Manuscript published: May 4, 2021 (version 1)
  4. Version of Record published: May 21, 2021 (version 2)

Copyright

© 2021, Zhou et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,722
    Page views
  • 306
    Downloads
  • 6
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Xin Zhou
  2. Seula Shin
  3. Chenxi He
  4. Qiang Zhang
  5. Matthew N Rasband
  6. Jiangong Ren
  7. Congxin Dai
  8. Rocío I Zorrilla-Veloz
  9. Takashi Shingu
  10. Liang Yuan
  11. Yunfei Wang
  12. Yiwen Chen
  13. Fei Lan
  14. Jian Hu
(2021)
Qki regulates myelinogenesis through Srebp2-dependent cholesterol biosynthesis
eLife 10:e60467.
https://doi.org/10.7554/eLife.60467

Further reading

    1. Developmental Biology
    Tsz Long Chu, Peikai Chen ... Kathryn Song Eng Cheah
    Research Article Updated

    Bone homeostasis is regulated by hormones such as parathyroid hormone (PTH). While PTH can stimulate osteo-progenitor expansion and bone synthesis, how the PTH-signaling intensity in progenitors is controlled is unclear. Endochondral bone osteoblasts arise from perichondrium-derived osteoprogenitors and hypertrophic chondrocytes (HC). We found, via single-cell transcriptomics, that HC-descendent cells activate membrane-type 1 metalloproteinase 14 (MMP14) and the PTH pathway as they transition to osteoblasts in neonatal and adult mice. Unlike Mmp14 global knockouts, postnatal day 10 (p10) HC lineage-specific Mmp14 null mutants (Mmp14ΔHC) produce more bone. Mechanistically, MMP14 cleaves the extracellular domain of PTH1R, dampening PTH signaling, and consistent with the implied regulatory role, in Mmp14ΔHC mutants, PTH signaling is enhanced. We found that HC-derived osteoblasts contribute ~50% of osteogenesis promoted by treatment with PTH 1–34, and this response was amplified in Mmp14ΔHC. MMP14 control of PTH signaling likely applies also to both HC- and non-HC-derived osteoblasts because their transcriptomes are highly similar. Our study identifies a novel paradigm of MMP14 activity-mediated modulation of PTH signaling in the osteoblast lineage, contributing new insights into bone metabolism with therapeutic significance for bone-wasting diseases.

    1. Biochemistry and Chemical Biology
    2. Developmental Biology
    Zengdi Zhang, Zan Huang ... Hai-Bin Ruan
    Research Article Updated

    In mammals, interactions between the bone marrow (BM) stroma and hematopoietic progenitors contribute to bone-BM homeostasis. Perinatal bone growth and ossification provide a microenvironment for the transition to definitive hematopoiesis; however, mechanisms and interactions orchestrating the development of skeletal and hematopoietic systems remain largely unknown. Here, we establish intracellular O-linked β-N-acetylglucosamine (O-GlcNAc) modification as a posttranslational switch that dictates the differentiation fate and niche function of early BM stromal cells (BMSCs). By modifying and activating RUNX2, O-GlcNAcylation promotes osteogenic differentiation of BMSCs and stromal IL-7 expression to support lymphopoiesis. In contrast, C/EBPβ-dependent marrow adipogenesis and expression of myelopoietic stem cell factor (SCF) is inhibited by O-GlcNAcylation. Ablating O-GlcNAc transferase (OGT) in BMSCs leads to impaired bone formation, increased marrow adiposity, as well as defective B-cell lymphopoiesis and myeloid overproduction in mice. Thus, the balance of osteogenic and adipogenic differentiation of BMSCs is determined by reciprocal O-GlcNAc regulation of transcription factors, which simultaneously shapes the hematopoietic niche.